1789 TT

ScinoPharm Investor Conference

— 2024 08 13

ScinoPharm Taiwan

Disclaimer

This material has been prepared by ScinoPharm Taiwan, Ltd. (“ScinoPharm”).

Any opinions expressed in this material are subject to change without notice as a result of using different assumptions. ScinoPharm is under no obligation to update or keep current the information contained herein. The **information contained** in this presentation **is** ScinoPharm’s **confidential** information.

Any disclosure, copying, distribution or any action taken or omitted to be taken in reliance on it is prohibited and may be unlawful.

No representation or warranty, express or implied, is or **will be made** in or in relation to, and no responsibility or liability is or will be accepted by the Company **as to**, the **accuracy or completeness** of this material and any liability therefore is hereby expressly disclaimed.

Statements made in this material include forward-looking statements, which include, without limitation, statements about the issues, plans and expectations of ScinoPharm. Without limiting the foregoing, statements including the words “believes”, “anticipates”, “plans”, “expects” and similar expressions are also forward-looking statements. Forward-looking statements reflect, among other things, management’s plans and objectives for future operations, current views with respect to future events and future economic performances and projections of various financial items. **These forward-looking statements involve known and unknown risks**, uncertainties and other factors **which may cause actual results to differ materially from those implied** by such forward-looking statements.

Agenda

01 Overview of Business Operations

02 Business Update

03 Financial Performance



Overview of Business Operations

I. Operational Growth Remains Steady

- In 1H 2024, our consolidated revenue reached US$51.64 million, marking a 13% YOY increase. Revenue in NTD was 1,646 million, reflecting a 17% YOY growth. Net income after tax was NT$215 million, up 117% compared to the same period last year.
- Both Taiwan ScinoPharm and ScinoPharm Changshu operations have progressed as planned, with solid development in our API business and robust growth in our injectables division.
- Our Taiwan injectables facility and Changshu API plant both underwent FDA inspections and successfully passed with zero deficiencies (Zero Form 483).

II. Enhancing In-house Product Capabilities

- **Rich pipeline in APIs**
  - We are expanding our core product portfolio and optimizing capacity utilization to strengthen our API foundation
  - We continue to enrich our product pipeline, leveraging our strengths in product development to seize key opportunities within the supply chain
- **Proprietary Injectable Products**
  - We are actively advancing the regulatory approval process for our proprietary injectable products to accelerate market entry in the United States
  - We are also extending regulatory filings and product deployment to non-U.S. markets
- **505(B)(2) Projects**
  - We are collaborating with partners to increase our involvement in the development of 505(b)(2) projects

III. Expanding CDMO Footprint

- We are focusing on the peptide, steroid, and cytotoxic product sectors, leveraging our R&D capabilities to continually expand our contract development and manufacturing services for new drug candidates
- By capitalizing on our expertise in complex peptide injectables and cytotoxic production, we are steadily broadening our injectable contract manufacturing portfolio, enhancing service offerings, and diversifying our partnerships. Simultaneously, we are optimizing site utilization and planning to build a comprehensive, integrated service platform



Business Updates

2024 Anticipated Approvals and Strategic Focus

Type	Product	Region	Indication	Brand Marketer	Regional * Sales (Mil., USD)
Generic API	Cladribine	CN(✓)	Multiple Sclerosis	Merck	5
Generic API	Olaparib	CN(✓)	Cancer	AstraZeneca	129
Generic API	Exemestane	CN(✓)	Breast Cancer	Pfizer	246
Generic API	Azacitidine	EU	Myelodysplastic syndromes	Celgene	384
Generic API	Dantrolene Na	EU	Malignant Hyperthermia	Eagles	11
CDMO API	Galantamine Benzoate Gluconate	US(✓)	Alzheimer's disease	Post-marketing Disclosure	NA
CDMO API	Eflornithine HCl	US/EU	Familial Adenomatous Polyposis	Post-marketing Disclosure	NA
CDMO API	Eflornithine HCl	EU	Neuroblastoma	Post-marketing Disclosure	NA
Generic Drug	Clofarabine	US	Acute Lymphoblastic Leukemia	Genzyme	3

✓：Approved / As of 2024/07/31

* Source：IQVIA Data (2023Q1-2023Q4)

Strengthening Core API Product Contributions

- Reinforcing our core API products by expanding key offerings, optimizing production costs to remain competitive in the markets, and increasing sales volume to extend our API foundation



* One oncology product added in 2024 Q2

Expanding CDMO Services

- **Focusing on our expertise in peptides, steroids, and cytotoxic products, we are leveraging our R&D capabilities to secure collaboration opportunities, thereby broadening the scope of our contract development services**



*One API product received FDA approval in July 2024, transitioning from Phase III to commercialized status

Drug Product Business Development

- **We are continuously expanding our injectable formulation product portfolio, aligning with our goal of providing vertical integration from API development to finished dosage forms**

Dosage Form	Project Numbers	Indication	Under Development	Technical Package Ready	Dossier Ready	Under Registration	Approved
Lyophilized Powder	4	• Myelodysplastic Syndromes • Multiple Myeloma • Oncology		1 1			1 1
Liquid Solution	6	• Leukemia • Oncology • Reversal of Neuromuscular Blockade		 4 1		1	
Prefilled Syringe	3	• Thromboembolic Disorders • Multiple Sclerosis • Medical Imaging Agents		 1		1	1
Cartridge in Device	4	• Osteoporosis • Diabetes Mellitus • Chronic Weight Management	1		1	1 1	

In-House Drug Product Status



Two in-house cartridge products submitted ANDA to FDA, and another one is preparing registration batch production

A product passed Pre-Approval Inspection with zero FDA-483 Form issued in Apr., 2024

*Responded to FDA CRL

China Business

- Leveraging the strengths of our Tainan and Changshu facilities, we are deepening our presence in the Chinese market, which is now entering a growth phase
- The Changshu plant, recognized for its flexible production support and strategic positioning in the Chinese market, achieved profitability in 2023 and is on a continued growth trajectory in 2024
- In March 2024, the Changshu facility underwent another FDA inspection, successfully passing with zero deficiencies (Zero Form 483), demonstrating our high standards of operation and enhancing our appeal to international companies and "dual filing" clients in the U.S. and China
- We have passed GMP compliance inspections for five products, which are now in full-scale commercial productions and supplies, with additional products progressing through the pipeline

Product	Indication	Sales in China*
Sodium Phenylbutyrate	Urea cycle disorders	Orphan disease medicine
Donafenib	Advanced liver cancer Thyroid cancer	c. USD 24.5 million
Bimatoprost	Glaucoma	c. USD 1.9 million
Azilsartan	Hypertension	c. USD 6.5 million
Olaparib	Cancer	c. USD 129 million

* Source：IQVIA Data (2023Q1-2023Q4)



Financial Performance

Consolidated Income Statement

NTD Million except for EPS	1H 2024		YoY	1H 2023	
Revenue	1,646	100%	17%	1,403	100%
Gross Profit	644	39%	22%	527	38%
Operating Expenses	(421)	(26%)	2%	(432)	(31%)
Operating Profit	223	13%	134%	95	7%
Net Profit before Tax	265	16%	123%	119	8%
Net Profit after Tax	215	13%	117%	99	7%
EPS (NTD)	0.27	-	-	0.13	-

Sales Distribution – By Business





Unit: USD/M

	Generic API	CDMO	Drug Product
1H 2024 Sales	33.3	12.5	5.8
YoY	-3.3%	75.1%	36.6%

Sales Distribution – By Indication





Unit: USD/M

	Oncology	CNS	Others
1H 2024 Sales	32.6	11.6	7.4
YoY	10.2%	1.0%	55.6%

Sales Distribution – By Region

Unit: USD/M

	US & Canada	EU	Japan	India	China	Others
1H 2024 Sales	8.3	10.1	7.6	7.1	10.0	8.5
YoY	19.9%	10.2%	1.2%	-25.5%	69.3%	25.1%

Consolidated Balance Sheet

NTD Million	2024/06/30		2023/06/30	
Cash and Cash Equivalents	4,207	35%	4,242	36%
Accounts Receivable	479	4%	556	5%
Inventories	1,815	15%	1,493	12%
Property, Plant & Equipment	3,755	31%	3,674	31%
Other Current/Non-Current Assets	1,740	15%	1,925	16%
Total Assets	**11,996**	**100%**	**11,890**	**100%**
Financial Debt	9	0%	80	1%
Other Current Liabilities	964	8%	1,001	8%
Other Non-Current Liabilities	651	6%	632	5%
Total Liabilities	1,624	14%	**1,713**	**14%**
Total Shareholders' Equities	**10,372**	**86%**	**10,177**	**86%**

Consolidated Cash Flow Statement

NTD million	1H 2024	1H 2023
From Operating Activities	**421**	**48**
Depreciation & Amortization	241	230
From Investing Activities	**(135)**	**(88)**
Capital Expenditure	(135)	(140)
From Financing Activities	**(31)**	**(2)**
Effect of foreign exchange rate changes	**10**	**(11)**
Net Change in Cash	**265**	**(53)**
Beginning Balance	**3,942**	**4,295**
Ending Balance	**4,207**	**4,242**



Q & A

Appendix
Company Overview

ScinoPharm at a Glance

- Est. 1997 in Taiwan with R&D/CGMP plants in Tainan and Changshu, China plus marketing forces in Tainan, Shanghai and Tokyo
- Specializes in providing R&D and CGMP manufacturing of APIs (cytotoxic/steroid) and injectable drug products
- 77 generic APIs in portfolio with 37 referred and approved ANDAs/NDAs*
  - 928 active DMFs worldwide with 66 US DMFs*
- 200+ contract projects with 13 approved/launched (11 NCEs) and 4 in phase 3 for NDA/MAA filing within 1-3 years*
- API plant certified by key international regulators - US FDA, EMA, EDQM, Australian TGA, Japanese PMDA, Korea KFDA, Mexico COFEPRIS and German Authority
- Injectable plant certified by US FDA and TFDA

*As of 2024/07/31

Brand Quality with Asian Advantages

www.scinopharm.com

1789 TT